Exciting announcement. My fingers are crossed similar results are achieved for the other trial participants.
The headline pecked my interest as the old man was knocked over by AML last year, 3 weeks from diagnosis to passing away. Incredibly aggressive disease, so I think a CR is pretty amazing and hopefully works for others. Even if it gives patients an extra 6 months of good living to do the things they want to do, people with AML should be queuing up imo.
I will follow with interest and likely purchase a few.
- Forums
- ASX - By Stock
- CHM
- Ann: AML patient achieves Complete Response in CHM CORE-NK trial
CHM
chimeric therapeutics limited
Add to My Watchlist
0.00%
!
0.4¢

Ann: AML patient achieves Complete Response in CHM CORE-NK trial, page-54
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
30 | 17137000 | 0.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.5¢ | 28294475 | 26 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
30 | 17137000 | 0.004 |
37 | 23631939 | 0.003 |
15 | 13500507 | 0.002 |
9 | 49600000 | 0.001 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.005 | 28294475 | 26 |
0.006 | 13747410 | 16 |
0.007 | 4700000 | 4 |
0.008 | 8542434 | 6 |
0.009 | 2767672 | 5 |
Last trade - 09.01am 18/06/2025 (20 minute delay) ? |
Featured News
CHM (ASX) Chart |
Day chart unavailable
The Watchlist
MEM
MEMPHASYS LIMITED.
Professor John Aitken, Scientific Director
Professor John Aitken
Scientific Director
Previous Video
Next Video
SPONSORED BY The Market Online